ClinicalTrials.gg

Program

dulaglutide

Also written as “Dulaglutide”, “LY2189265” and “Dulaglutide (Reference)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 3 companies.

Furthest: phase 4, since Apr 21, 201647 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly451 open or runningphase 4since Apr 21, 2016Feb 28, 2008Dec 2027phase 3 · NCT06739122
CSPC Pharmaceutical Group10 open or runningphase 3since Jan 23, 2024Jan 23, 2024none ahead
Innovent Biologics10 open or runningphase 3since Oct 19, 2022Oct 19, 2022none ahead

Also a collaborator on its studies: united-biosource-llc and tessella-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 32 studies since Feb 28, 2008.

  1. Nov 10, 2016Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT02963766 · 154 enrolled · United States, Brazil, France and more
  2. Nov 22, 2016Phase 2 study in Diabetes Mellitus, Type 2Eli Lilly · NCT02973100 · 318 enrolled · United States, Czechia, Mexico and more
  3. Oct 17, 2017Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT03315780 · 12 enrolled · Japan
  4. Dec 1, 2017Phase 1 study in HealthyEli Lilly · NCT03363906 · 27 enrolled · United States
  5. Apr 2, 2018Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT03495102 · 1,842 enrolled · United States, Argentina, Austria and more
  6. Oct 16, 2020Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04591626 · 291 enrolled · China
  7. Nov 20, 2020Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04641312 · 67 enrolled · Germany
  8. Mar 19, 2021Phase 3 study in Diabetes MellitusEli Lilly · NCT04809220 · 591 enrolled · Japan
  9. May 16, 20222 phase 1 studies in Diabetes Mellitus, Type 2Eli Lilly · NCT05377333, NCT05407961
  10. Oct 19, 2022Innovent Biologics's first study: phase 3 study in Diabetes Mellitus, Type 2New to Innovent BiologicsInnovent Biologics · NCT05606913 · 731 enrolled · China
  11. Dec 15, 2022Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT05659537 · 212 enrolled · India
  12. Jan 23, 2024CSPC Pharmaceutical Group's first study: phase 3 study in Diabetes Mellitus, Type 2New to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06235086 · 632 enrolled · China
  13. Dec 13, 2024Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06739122 · 55 planned · United States, Argentina, Mexico
  14. Dec 18, 2025Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07313813 · 20 enrolled · Singapore

Ahead

  1. Dec 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06739122

TargetBeta

GLP1R →read by rule
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently ”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319
efpeglenatideruleHanmi Pharmaceuticalphase 313

Studies

All 47 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07313813Diabetes Mellitus, Type 2 · Singapore1CompletedEli LillyAug 13, 202620
NCT06739122Diabetes Mellitus, Type 2 · United States, Argentina, Mexico3RecruitingEli LillyDec 202755
NCT06235086Diabetes Mellitus, Type 2 · China3CompletedCSPC Pharmaceutical GroupFeb 3, 2026632
NCT05659537Diabetes Mellitus, Type 2 · India4CompletedEli LillyJan 16, 2024212
NCT05606913Diabetes Mellitus, Type 2 · China3CompletedInnovent BiologicsJan 26, 2024731
NCT05407961Diabetes Mellitus, Type 2 · Germany1CompletedEli LillyJan 12, 202490
NCT05377333Diabetes Mellitus, Type 2 · United States1CompletedEli LillyNov 22, 202394
NCT04809220Diabetes Mellitus · Japan3CompletedEli LillyOct 1, 2022591
NCT04641312Diabetes Mellitus, Type 2 · Germany1CompletedEli LillyDec 21, 202167
NCT04591626Diabetes Mellitus, Type 2 · China3CompletedEli LillyApr 28, 2022291
NCT03495102Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedEli LillyMay 28, 20191,842
NCT03363906Healthy · United States1CompletedEli LillyJun 6, 201827
NCT03315780Diabetes Mellitus, Type 2 · Japan4CompletedEli LillyFeb 28, 201812
NCT02973100Diabetes Mellitus, Type 2 · United States, Czechia, Mexico and more2CompletedEli LillyJul 15, 2017318
NCT02963766Diabetes Mellitus, Type 2 · United States, Brazil, France and more3CompletedEli LillyJun 12, 2021154
NCT02750410Diabetes Mellitus, Type 2 · Japan4CompletedEli LillyJun 18, 2018159
NCT02597049Diabetes Mellitus, Type 2 · United States, Austria, Czechia and more3CompletedEli LillyFeb 2017424
NCT02152371Diabetes Mellitus, Type 2 · United States, Czechia, Hungary and more3CompletedEli LillyOct 2015300
NCT01769378Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedEli LillyDec 2014300
NCT01667900Diabetes Mellitus, Type 2 · China1CompletedEli LillyJun 201458
NCT01644500Diabetes Mellitus, Type 2 · China, Korea, Republic of, Taiwan3CompletedEli LillyAug 2014737
NCT01648582Diabetes Mellitus, Type 2 · China, Korea, Republic of, Mexico and more3CompletedEli LillyAug 2014774
NCT01624259Diabetes Mellitus, Type 2 · United States, Czech Republic, Germany and more3CompletedEli LillyNov 2013599
NCT01621178Diabetes Mellitus, Type 2 · United States, Brazil, Hungary and more3CompletedEli LillyJun 2016577
NCT01584232Diabetes Mellitus, Type 2 · Japan3CompletedEli LillyJul 2013361
NCT01558271Diabetes Mellitus, Type 2 · Japan3CompletedEli LillyOct 2013492
NCT01524770Diabetes Mellitus, Type 2 · United States1CompletedEli LillyJun 201250
NCT01458210Diabetes Mellitus, Type 2 · United States1CompletedEli LillyFeb 201222
NCT01436201Diabetes Mellitus, Type 2 · United States1CompletedEli LillyNov 201124
NCT01432938Diabetes Mellitus, Type 2 · United States1CompletedEli LillyDec 201128
NCT01408888Diabetes Mellitus, Type 2 · United States1CompletedEli LillyApr 201229
NCT01394952Cardiovascular Diseases · United States, Argentina, Australia and more3CompletedEli LillyAug 21, 20189,901
NCT01324388Diabetes Mellitus, Type 2 · United States1CompletedEli LillyAug 201151
NCT01301092Diabetes Mellitus, Type 2 · United States1CompletedEli LillyAug 201130
NCT01300260Diabetes Mellitus, Type 2 · Germany1CompletedEli LillyAug 201132
NCT01253304Diabetes Mellitus, Type 2 · Germany, Hungary1CompletedEli LillyNov 201126
NCT01250834Healthy Volunteers · United Kingdom1CompletedEli LillyMar 201127
NCT01215968Diabetes Mellitus, Type 2 · United Kingdom1CompletedEli LillyJul 201138
NCT01191268Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedEli LillyFeb 2012884
NCT01149421Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more2CompletedEli LillySep 2011755
NCT01126580Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedEli LillyNov 2011807
NCT01075282Diabetes Mellitus, Type 2 · Argentina, Australia, Belgium and more3CompletedEli LillyMay 2012810
NCT01064687Diabetes Mellitus, Type 2 · United States, Argentina, Mexico and more3CompletedEli LillyNov 2011978
NCT01001104Diabetes Mellitus, Type 2 · Japan2CompletedEli LillyDec 2010145
NCT00791479Diabetes Mellitus, Type 2 · United States, Croatia, Denmark and more2CompletedEli LillyJan 2010167
NCT00734474Diabetes Mellitus, Type 2 · United States, Canada, France and more3CompletedEli LillyJun 20111,202
NCT00630825Diabetes Mellitus, Type 2 · United States, Puerto Rico2CompletedEli LillyJan 2009262

How it is read

Names in the registry

  • “Dulaglutide”, 25 entries
  • “LY2189265”, 18 entries
  • “dulaglutide”, 2 entries
  • “Dulaglutide (Reference)”, 1 entry
  • “Dulaglutide (Test)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.